James Godfrey Michael R Bishop Sahr Syed Elizabeth Hyjek Justin Kline
10.1186/s40425-017-0211-z
J Immunother Cancer
2017 Feb 21;5:11.
allogeneic transplant checkpoint blockade hodgkin lymphoma pd-1
CC BY
https://pubmed.ncbi.nlm.nih.gov/28239465/
Antibodies, Monoclonal / therapeutic use Antineoplastic Agents / therapeutic use Hodgkin Disease / drug therapy Hodgkin Disease / therapy Programmed Cell Death 1 Receptor / antagonists & inhibitors
Antibodies, Monoclonal / therapeutic use Antineoplastic Agents / therapeutic use Hodgkin Disease / drug therapy Hodgkin Disease / therapy Programmed Cell Death 1 Receptor / antagonists & inhibitors Case Reports Adult Antibodies, Monoclonal / adverse effects Antineoplastic Agents / adverse effects Hematopoietic Stem Cell Transplantation Humans Male Middle Aged Nivolumab Recurrence Remission Induction Transplantation, Homologous Antibodies, Monoclonal Antineoplastic Agents PDCD1 protein, human Programmed Cell Death 1 Receptor Nivolumab
PMC5319147
28239465
PD-1 blockade induces remissions in relapsed classical Hodgkin lymphoma following allogeneic hematopoietic stem cell transplantation
2017